We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Susceptibility Loci for Colorectal Cancer Identified by Genome-Wide Association Studies on East Asians

By LabMedica International staff writers
Posted on 07 Jan 2013
A genome-wide association study (GWAS) conducted on individuals from several East Asian countries identified four genetic foci linked to colorectal cancer, three of which were also found in a population of European descent.

A GWAS is an examination of many common genetic variants in different individuals to see if any variant is associated with a trait. More...
A GWAS typically focuses on associations between single-nucleotide polymorphisms (SNPs) and traits such as major diseases. These studies normally compare the DNA of two groups of participants: people with the disease (cases) and similar people without (controls). Each person gives a sample of DNA, from which millions of genetic variants are read using SNP arrays. If one type of the variant is more frequent in people with the disease, the SNP is said to be "associated" with the disease. The associated SNPs are then considered to mark a region of the human genome, which influences the risk of disease. In contrast to methods that specifically test one or a few genetic regions, a GWAS investigates the entire genome. A GWAS identifies SNPs and other variants in DNA, which are associated with a disease, but cannot on its own specify which genes cause the illness.

In a paper published in the December 23, 2012, online edition of the journal Nature Genetics investigators at Vanderbilt University (Nashville, TN, USA) searched for new genetic factors associated with colorectal cancer (CRC) by conducting a GWAS on an East Asian test group comprising 2,098 cases and 5,749 controls. From this group they selected 64 promising SNPs for replication in an independent set of samples, including up to 5,358 cases and 5,922 controls. Results of the second study yielded four foci linked to CRC. Three of the four were replicated in a study conducted in 26,060 individuals of European descent.

"Looking at different ethnic groups is important because the genetic structures can be different enough that variants identified in one population do not explain risk in other populations," said senior author Dr. Wei Zheng, professor of cancer research at Vanderbilt University. "Because of the difference in genetic structures and underlying environment exposures, it might be easier to discover some risk variants in studies conducted in non-European populations."

"The findings from this study are relevant to both Asian and European populations," said Dr. Zheng. "Interestingly, these three susceptibility loci were not discovered in previous studies conducted in European-ancestry populations. These new discoveries are very exciting. They will certainly lead to future studies regarding the biology of these regions and the translational potential of these findings in cancer prevention and treatment."

Related Links:
Vanderbilt University


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.